OBJECTIVE: To examine the effectiveness of routine clinic review in detecting relapse after treatment for Hodgkin's disease. DESIGN: Review of hospital records. SETTING: Regional centre for cancer treatment and research. SUBJECTS:210 patients with Hodgkin's disease recruited to a chemotherapy trial protocol between 1984 and the end of 1990 who had achieved a complete or partial remission after treatment. MAIN OUTCOME MEASURES: The number of clinic visits made by patients over the period of observation, the number of relapses occurring during that time, and the route by which relapse was detected. RESULTS: The 210 patients generated 2512 outpatient reviews, and 37 relapses were detected. Thirty relapses (81%) were diagnosed in patients who described symptoms, which in 15 cases had resulted in an earlier appointment being arranged. In only four cases (11%; 95% confidence interval 4% to 25%) was relapse detected as a result of routine physical examination on investigation of a patient who did not have symptoms. CONCLUSIONS: Relapse of Hodgkin's disease after treatment is usually detected as a result of the investigation of symptoms rather than by routine screening of asymptomatic patients. It is therefore proposed that the frequency of routine follow up visits should be reduced and greater emphasis placed on patient education. This should underline the importance of symptoms and encourage patients to arrange an earlier appointment if these develop.
RCT Entities:
OBJECTIVE: To examine the effectiveness of routine clinic review in detecting relapse after treatment for Hodgkin's disease. DESIGN: Review of hospital records. SETTING: Regional centre for cancer treatment and research. SUBJECTS: 210 patients with Hodgkin's disease recruited to a chemotherapy trial protocol between 1984 and the end of 1990 who had achieved a complete or partial remission after treatment. MAIN OUTCOME MEASURES: The number of clinic visits made by patients over the period of observation, the number of relapses occurring during that time, and the route by which relapse was detected. RESULTS: The 210 patients generated 2512 outpatient reviews, and 37 relapses were detected. Thirty relapses (81%) were diagnosed in patients who described symptoms, which in 15 cases had resulted in an earlier appointment being arranged. In only four cases (11%; 95% confidence interval 4% to 25%) was relapse detected as a result of routine physical examination on investigation of a patient who did not have symptoms. CONCLUSIONS: Relapse of Hodgkin's disease after treatment is usually detected as a result of the investigation of symptoms rather than by routine screening of asymptomatic patients. It is therefore proposed that the frequency of routine follow up visits should be reduced and greater emphasis placed on patient education. This should underline the importance of symptoms and encourage patients to arrange an earlier appointment if these develop.
Authors: Stephan D Voss; Lu Chen; Louis S Constine; Allen Chauvenet; Thomas J Fitzgerald; Sue C Kaste; Thomas Slovis; Cindy L Schwartz Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: Jessica Hunn; Meaghan E Tenney; Ana I Tergas; Erin A Bishop; Kathleen Moore; William Watkin; Carolyn Kirschner; Jean Hurteau; Gustavo C Rodriguez; Ernst Lengyel; Nita K Lee; S Diane Yamada Journal: Gynecol Oncol Date: 2015-03-30 Impact factor: 5.482
Authors: Ajay K Gopal; Robert Chen; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Xuedong Chi; Eric L Sievers; Anas Younes Journal: Blood Date: 2014-12-22 Impact factor: 22.113
Authors: Tarec Christoffer El-Galaly; Karen Juul Mylam; Peter Brown; Lena Specht; Ilse Christiansen; Lars Munksgaard; Hans Erik Johnsen; Annika Loft; Anne Bukh; Victor Iyer; Anne Lerberg Nielsen; Martin Hutchings Journal: Haematologica Date: 2011-12-29 Impact factor: 9.941
Authors: Alison M Friedmann; Julie A Wolfson; Melissa M Hudson; Howard J Weinstein; Michael P Link; Amy Billett; Eric C Larsen; Torunn Yock; Sarah S Donaldson; Karen Marcus; Matthew J Krasin; Scott C Howard; Monika L Metzger Journal: Pediatr Blood Cancer Date: 2013-05-15 Impact factor: 3.167